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ABSTRACT 
 
Atrial fibrillation in patients with heart failure with reduced 
left ventricular ejection fraction is common and is associated 
with an increased risk of mortality, hospitalization and all-cause 
death. Rhythm control via medical treatment in these patients is 
restricted to use of amiodarone as the only suitable 
antiarrhythmic drug with the least proarrhythmic effect 
compared to other antiarrhythmic drugs for this population of 
patients. Over the last years there is a growing evidence that 
catheter ablation is beneficial in patients with heart failure since 
randomized clinical trials with hard endpoints have already been 
published. However, there are still unanswered questions about 
the patient categories that could benefit from the ablation 
procedures and the optimal ablation strategies in these patients. 
These issues are herein reviewed. Rhythmos 2018;13(4):75-77. 
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Abbreviations: AAD = antiarrhythmic drug; AF = atrial 
fibrillation; CA = catheter ablation; CFAE = complex 
fractionated atrial electrograms; HF = heart failure; HFpEF = 
heart failure with preserved ejection fraction; LGE = late 
gadolinium enhancement; LV = left ventric-le(-ular); LVEF = 
left ventricular ejection fraction; MRI = magnetic resonance 
imaging; NNT = number needed to treat; NYHA = New York 
Heart Association; PVI = pulmonary vein isolation 
 
INTRODUCTION 
 
Atrial fibrillation (AF) is the most common arrhythmia 
in the general population and is associated usually with 
significant symptoms and high rates of hospitalization and 
mortality. The prevalence of AF in the general population 
is 1.0– LQFUHDVLQJ WR  LQ SDWLHQWV DJHG 
years.1,2 Atrial fibrillation and heart failure (HF) frequently 
co-exist since there are common pathophysiologic 
pathways involved in both of them. Heart failure increases 
mean right and left atrial pressures promoting their 
progressive dilation. Data from the Framingham study 
demonstrated that in AF patients, occurrence of HF was 
associated with significant increase in mortality, while in 
HF patients, new-onset AF was associated with significant 
rise on mortality.3 
Nowadays, catheter ablation (CA) has emerged as a 
more effective treatment strategy compared to 
antiarrhythmic drugs (AADs) especially for patients with 
paroxysmal AF. Many observational and randomized trials 
have compared CA with AADs in patients with HF and AF 
and the latest guidelines from the European Society of 
Cardiology (ESC) recommend CA in this population when 
it is performed by experienced operators and after careful 
consideration of the benefits over the possible 
complications.4,5 Thus, there are unanswered questions 
regarding firstly the characteristics of the ideal patient with 
HF who should undergo CA and secondly the optimal CA 
strategy. 
 
RANDOMIZED CLINICAL TRIALS OF CATHETER 
$%/$7,21 ,1 3$7,(176 :,7+ $75,$/
FIBRILLATION AND HEART FAILURE   
 
Early clinical trials enrolled a small number of patients 
assessing end points such as left ventricle ejection fraction 
(LVEF) and quality of life but not hard clinical end points 
such as mortality. During the last years, a number of 
randomized clinical trials regarding the efficacy of AF 
ablation in patients with HF compared to AADs have been 
published.  
Patients with persistent AF, symptomatic HF, and 
LVEF <50% were randomized to CA or medical rate 
control in the CAMTAF study. Totally 55 patients were 
finally enrolled with a high proportion of non-ischemic 
cardiomyopathy and persistent AF, and the primary end-
point was the difference between groups in LVEF at 6 
months. An improvement in LVEF, peak oxygen 
consumption and quality of life score was seen in the 
ablation group versus the medical rate control group.6  
In the Ablation versus Amiodarone for Treatment of 
Atrial Fibrillation in Patients with Congestive Heart 
Failure and an Implanted Device (AATAC) study, CA 
(pulmonary vein isolation r substrate modification) was 
compared with amiodarone, as rhythm control strategy, in 
patients with persistent AF, systolic LV dysfunction 
(LVEF<40 %) and NYHA Class II–III heart failure. The 
primary endpoint of this study was AF recurrence during 
the two years of follow up and the secondary endpoints 
included all-cause mortality and hospitalizations. The 
patients in the CA group had significantly higher rates of 
freedom from AF (70 %) compared with the amiodarone 
(34 %) group. It must be noted that all patients in both 
groups had a cardiac implantable device, pacemaker or 
defibrillator, which improved the reliability of the follow 
up process. Both all-cause mortality and hospitalizations 
were also reduced and LVEF was significantly improved 
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in patients who underwent CA. Moreover, the number 
needed to treat (NNT) to avoid one hospitalization or one 
death was 3.8 and 10 patients for CA versus amiodarone, 
respectively.7 
The CAMERA-MRI trial (Catheter Ablation Versus 
Medical Rate Control in Atrial Fibrillation and Heart 
Failure) randomized 68 patients with persistent AF and 
idiopathic cardiomyopathy (LVEF <45 %) to receive 
either CA or medical rate control. All patients underwent 
a cardiac magnetic resonance imaging (MRI) scan in order 
to assess LVEF and to evaluate the presence of ventricular 
fibrosis via late gadolinium enhancement (LGE). The 
primary endpoint of this study was the change in LVEF 
after a 6-month follow up period. Patients who were 
randomized to the ablation group showed improved LVEF 
compared with the medical rate control group. It is 
important to note that 58% versus 9% in both groups had a 
QRUPDO /9()  DIWHU  PRQWKV 0RUHRYHU WKH
improvement in LVEF was significantly better in the 
ablation group patients with negative LGE at baseline 
compared to those with positive LGE. This indicates that 
restoration and maintenance of sinus rhythm in patients 
with reduced LV systolic function due to tachycardia – 
induced cardiomyopathy (without evidence of fibrosis) 
contributes to the improvement even in normalization of 
cardiac function.8 
One of the most important trials in the field of CA in 
patients with AF and HF was the CASTLE-AF which 
randomized 363 patients (>3000 screened for eligibility) 
suffering from symptomatic AF (30% had paroxysmal AF) 
and systolic dysfunction with LV()1<+$FODVV!
II to either radiofrequency CA or medical treatment. All 
patients had an implantable cardioverter defibrillator 
(ICD) or cardiac resynchronization therapy-defibrillator 
(CRT-D) device and the median follow up period was 37.8 
months.  The great importance of this study is the fact that 
is the first one designed to provide an answer in clinical 
hard endpoints, such as composite of all-cause mortality or 
hospitalization for worsening HF. The composite endpoint 
of all-cause mortality and hospitalization for HF was 
significantly lower in the ablation group compared to the 
control group (28.5% vs 44.6%, p=0.006) and the NNT to 
prevent one primary endpoint event was 6 patients. 
Moreover, after 60 months of follow-up, LVEF in the CA 
group had increased by 9% compared with the medical 
therapy group. The ablation strategy in this study included 
pulmonary vein isolation plus additional lesions involving 
the cavotricuspid isthmus, and left atrium substrate 
modification according to the preferences of the operator.9 
A possible limitation of the CASTLE-AF study was the 
fact that the positive results of catheter ablation were 
observed in symptomatic patients without advanced HF 
the majority of whom had previously failed AAD 
treatment. Also, patients with LVEF<25% seem to derive 
no benefit from CA compared to other patients. :LWK
regards to the catheter ablation related complication rates 
in patients with HF, serious adverse events occurred in 7.8 
%.9 
 
&$7+(7(5 $%/$7,21 ,1 3$7,(176 :,7+ $)
$1'+):,7+35(6(59('(-(&7,21)5$&7,21 
 
Few studies have examined outcomes of CA in 
patients with AF and heart failure with preserved ejection 
fraction (HFpEF). A retrospective study of 230 patients 
with HF who underwent AF ablation, including 133 with 
HFpEF was published recently evaluating symptoms and 
freedom from atrial arrhythmia at 12-months. There was 
no significant difference in adverse events and symptoms 
between patients with HFpEF compared to those with 
reduced LVEF with similar improvements in NYHA class 
in both groups.10 
Another study enrolled patients with normal and 
abnormal LV function who underwent CA for AAD-
refractory AF. Three groups of patients were compared: 
patients with systolic dysfunction (L9()  ZLWK
LVRODWHGGLDVWROLFG\VIXQFWLRQDQGSUHVHUYHG/9()
and with normal LV function. The primary end point was 
freedom from AF at 1 year after ablation without AADs 
use. This was achieved in 62% of patients with systolic 
dysfunction, 75% of those with diastolic dysfunction, and 
84% of controls (P=0.007). In the systolic dysfunction 
JURXSH[SHULHQFHGDQLQFUHDVHLQ/9()E\DIWHU
ablation, of which 64% achieved normal LVEF. In the 
diastolic dysfunction group, 30% of patients demonstrated 
at least 1 grade improvement in diastolic dysfunction.11 
 
:+,&+,67+(,'($/$)$%/$7,21675$7(*<,1
3$7,(176:,7++)? 
 
Patients with HF is more likely to suffer from 
persistent than paroxysmal AF. The ablation strategy in 
patients with persistent AF is not common across different 
electrophysiology centers and can include pulmonary vein 
isolation (PVI) alone or additionally linear ablation and/or 
ablation of complex fractionated atrial electrograms 
(CFAE). Besides, it is known from the Substrate and 
Trigger Ablation for Reduction of Atrial Fibrillation Trial 
Part II (STAR AF II) that no difference between these two 
strategies have been observed in patients with persistent 
AF. 12All the studies mentioned above have had significant 
differences both in the ablation strategy adopted by each 
operator and in the population characteristics. A meta-
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analysis of clinical and observational studies in patients 
with HF, showed similar percentages of sinus rhythm 
maintenance between a PVI approach versus extensive left 
atrial ablation (linear lesions or CFAE ablation).13 On the 
other hand, the structural and the subsequent 
electrophysiological abnormalities in the left atrium of 
patients with HF enforce the adoption of different ablation 
strategies according to the primary atrial substrate and to 
the type of cardiomyopathy (e.g. ischemic vs. hypertophic 
cardiomyopathy). In a recent study, a more aggressive 
ablation with left atrial substrate modification additionally 
to PVI resulted in better outcomes in patients with HF 
compared to those without HF as regards the AF 
recurrences after one year follow up.14 The optimal AF 
ablation strategy is different for each patient category and 
greatly depends on the degree of left or bi-atrial fibrosis. 
In this field, the contribution of MRI scan with LGE may 
give additional information about the left atrium 
characteristics and although it is not a widely used method 
for evaluation of CA outcomes, it may in the near future 
be more accessible in clinical practice. An ongoing study 
(DECAAF-II) will provide further data about the impact of 
targeting LGE-MRI detected atrial fibrosis during AF 
ablation to improve procedural outcomes.15 
 
CONCLUSIONS 
 
Atrial fibrillation ablation seems to have beneficial 
effects compared to medical treatment in selected patients 
with HF reducing the recurrences and the unplanned 
hospitalizations additionally to quality of life indexes. 
CASTLE-AF was a landmark randomized trial with hard 
end points such as death and hospitalization rates which 
showed superiority of CA to medical therapy, thus 
establishing CA as first line therapy in patients with HF 
with reduced LVEF. More data is required in order to 
identify the more appropriate patients with HF who could 
benefit from the CA procedures.    
 
REFERENCES 
 
1. /LS*<.DNDU3:DWVRQ7$WULDOILEULOODWLRQ— 
the growing epidemic. Heart 2007;93:542–43. 
2. 3LFFLQL -3 )DXFKLHU / 5K\WKP FRQWURO LQ DWULDO
fibrillation. Lancet 2016;388:829–40. 
3. :DQJ 7- /DUVRQ 0* /HY\ ' HW DO 7HPSRUDO
relations of atrial fibrillation and congestive heart 
failure and their joint influence on mortality: the 
Framingham Heart Study. Circulation 2003;107: 
2920-25. 
4. Dagres N, Varounis C, Gaspar T, et al. Catheter 
ablation for atrial fibrillation in patients with left 
ventricular systolic dysfunction. A systematic review 
and meta-analysis. J Card Fail 2011;17:964–70. 
5. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC 
Guidelines for the management of atrial fibrillation 
developed in collaboration with EACTS. Eur Heart J 
2016;37:2893–962. 
6. +XQWHU5-%HUULPDQ7-'LDE,HWDO$UDQGRPLVHG
controlled trial of catheter ablation versus medical 
treatment of atrial fibrillation in heart failure (the 
CAMTAF trial). Circ Arrhythm Electrophysiol 2014; 
7:31–38.  
7. Di Biase L, Mohanty P, Mohanty S, et al. Ablation 
versus amiodarone for treatment of persistent atrial 
fibrillation in patients with congestive heart failure and 
an implanted device: results from the AATAC 
Multicenter randomized trial. Circulation 2016; 
133:1637–44. 
8. 3UDEKX 6 7D\ORU $- &RVWHOOR %7 HW DO &DWKHWHU
ablation versus medical rate control in atrial 
fibrillation and systolic dysfunction: the CAMERA-
MRI study. J Am Coll Cardiol 2017;70:1949–61. 
9. Marrouche NF, BrachPDQQ - $QGUHVHQ ' HW DO
Catheter ablation for atrial fibrillation with heart 
failure. N Engl J Med 2018;378:417–27. 
10. Black-Maier E, Ren X, Steinberg BA, et al. Catheter 
ablation of atrial fibrillation in patients with heart 
failure and preserved ejection fraction. Heart Rhythm 
2018;15:651-57. 
11. &KD<0:RNKOX$$VLUYDWKDP6-HWDO6XFFHVVRI
ablation for atrial fibrillation in isolated left ventricular 
diastolic dysfunction: a comparison to systolic 
dysfunction and normal ventricular function. Circ 
Arrhythm Electrophysiol 2011;4:724-32. 
12. 9HUPD$ -LDQJ&<%HWWV75 HW DO$SSURDFKHV WR
catheter ablation for persistent atrial fibrillation. N 
Engl J Med 2015;372:1812–22. 
13. Anselmino M, Matta M, D’Ascenzo F, et al. Catheter 
ablation of atrial fibrillation in patients with left 
ventricular systolic dysfunction: a systematic review 
and meta-analysis. Circ Arrhythm Electrophysiol 
2014;7:1011–18. 
14. +DOGDU6.-RQHV'*.KDQ+HWDO&KDUDFWHULVLQJ
the difference in electrophysiological substrate and 
outcomes between heart failure and non-heart failure 
patients with persistent atrial fibrillation. Europace 
2017;20:451–458. 
15. https://clinicaltrials.gov/ct2/show/NCT02529319 
 
 
  
